Clinical Trials: Making a Difference
Early findings from the Komen-funded RxPONDER (Rx for Positive Node, Endocrine Responsive Breast Cancer) study indicate some postmenopausal women with lymph node-positive, hormone receptor-positive, HER2-negative breast cancer do not benefit from chemotherapy when it is added to hormone therapy. These women may be able to safely avoid chemotherapy and its harmful side effects. In contrast, premenopausal women benefitted from chemotherapy.
